Technical Analysis for INM - InMed Pharmaceuticals Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.36 | -1.36% | 0.00 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
50 DMA Resistance | Bearish | -1.36% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.36% | |
Calm After Storm | Range Contraction | -1.36% | |
Wide Bands | Range Expansion | -1.36% | |
Oversold Stochastic | Weakness | -1.36% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 11 hours ago |
Fell Below 10 DMA | about 11 hours ago |
10 DMA Support | about 12 hours ago |
Rose Above 50 DMA | about 12 hours ago |
1.5x Volume Pace | about 12 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/14/2024
InMed Pharmaceuticals Inc. Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Disease Rare Diseases Cannabis Pharmacology Dermatology Stage Pharmaceutical Glaucoma Toxicology Genodermatoses Cannabinoid Treatment Of Glaucoma Epidermolysis Bullosa Ocular Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.08 |
52 Week Low | 0.2913 |
Average Volume | 180,955 |
200-Day Moving Average | 0.66 |
50-Day Moving Average | 0.37 |
20-Day Moving Average | 0.38 |
10-Day Moving Average | 0.36 |
Average True Range | 0.04 |
RSI (14) | 45.36 |
ADX | 33.59 |
+DI | 28.98 |
-DI | 9.29 |
Chandelier Exit (Long, 3 ATRs) | 0.34 |
Chandelier Exit (Short, 3 ATRs) | 0.45 |
Upper Bollinger Bands | 0.44 |
Lower Bollinger Band | 0.32 |
Percent B (%b) | 0.28 |
BandWidth | 32.17 |
MACD Line | -0.01 |
MACD Signal Line | 0.00 |
MACD Histogram | -0.0039 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.39 | ||||
Resistance 3 (R3) | 0.39 | 0.38 | 0.39 | ||
Resistance 2 (R2) | 0.38 | 0.37 | 0.38 | 0.38 | |
Resistance 1 (R1) | 0.37 | 0.37 | 0.36 | 0.37 | 0.38 |
Pivot Point | 0.36 | 0.36 | 0.35 | 0.36 | 0.36 |
Support 1 (S1) | 0.34 | 0.35 | 0.34 | 0.34 | 0.33 |
Support 2 (S2) | 0.33 | 0.34 | 0.33 | 0.33 | |
Support 3 (S3) | 0.32 | 0.33 | 0.32 | ||
Support 4 (S4) | 0.32 |